

November 10, 2023



# Atara Biotherapeutics To Participate at the Stifel Healthcare Conference

THOUSAND OAKS, Calif.--(BUSINESS WIRE)-- [Atara Biotherapeutics, Inc.](#) (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a fireside chat at the Stifel Healthcare Conference in New York on Tuesday, November 14, 2023 at 8:30 a.m. PST / 11:30 a.m. EST.

A live webcast of the presentation will be available by visiting the [Investors and Media](#) section of [atarabio.com](#). An archived replay of the webcast will be available on the Company's website for 30 days following the live presentation.

## About Atara Biotherapeutics, Inc.

Atara is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions, including multiple sclerosis, that can be rapidly delivered to patients within days. With cutting-edge science and differentiated approach, Atara is the first company in the world to receive regulatory approval of an allogeneic T-cell immunotherapy. Our advanced and versatile Epstein-Barr virus (EBV) T-cell platform does not require T-cell receptor or HLA gene editing and forms the basis of a diverse portfolio of investigational therapies that target EBV, the root cause of certain diseases, in addition to next-generation AlloCAR-Ts designed for best-in-class opportunities across a broad range of non-EBV-associated liquid and solid tumors. Atara is headquartered in Southern California. For more information, visit [atarabio.com](#) and follow [@Atarabio](#) on [X](#) (formerly known as Twitter) and [LinkedIn](#).

View source version on businesswire.com:

<https://www.businesswire.com/news/home/20231109837801/en/>

## Investor and Media Relations

Alex Chapman

Vice President, Corporate Communications & Investor Relations

(805) 456-4772

[achapman@atarabio.com](mailto:achapman@atarabio.com)

Jason Awe, Ph.D.

Senior Director, Corporate Communications & Investor Relations

(805) 217-2287

[jawe@atarabio.com](mailto:jawe@atarabio.com)

Source: Atara Biotherapeutics, Inc.